Cargando…

SARS‐CoV‐2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy

Mathematical models of viral dynamics have been reported to describe adequately the dynamic changes of severe acute respiratory syndrome‐coronavirus 2 viral load within an individual host. In this study, eight published viral dynamic models were assessed, and model selection was performed. Viral loa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shengyuan, Agyeman, Akosua A., Hadjichrysanthou, Christoforos, Standing, Joseph F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583246/ https://www.ncbi.nlm.nih.gov/pubmed/37534815 http://dx.doi.org/10.1002/psp4.13022

Ejemplares similares

Comparative assessment of viral dynamic models for SARS‐CoV‐2 for pharmacodynamic assessment in early treatment trials
por: Agyeman, Akosua A., et al.
Publicado: (2022)

Learning and confirming in publicly funded antiviral trials
por: Standing, Joseph F, et al.
Publicado: (2023)

How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?
por: Vegvari, Carolin, et al.
Publicado: (2016)

Systematic Review and Patient‐Level Meta‐Analysis of SARS‐CoV‐2 Viral Dynamics to Model Response to Antiviral Therapies
por: Gastine, Silke, et al.
Publicado: (2021)

Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities
por: Stylianou, Andria, et al.
Publicado: (2017)

Initiation of Antiviral Treatment in SARS‐CoV2: Modeling Viral Dynamics and Drug Properties
por: Rosenbloom, Daniel Scholes, et al.
Publicado: (2020)

Models of kleptoparasitism on networks: the effect of population structure on food stealing behaviour
por: Hadjichrysanthou, Christoforos, et al.
Publicado: (2017)

What is the process of obtaining informed consent in a clinical trial? Is it ever justifiable to include someone in a clinical trial without prior informed consent from the individual?
por: Agyeman, Akosua Adom, et al.
Publicado: (2016)

Modeling the viral dynamics of SARS-CoV-2 infection
por: Wang, Sunpeng, et al.
Publicado: (2020)

Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community
por: Hadjichrysanthou, Christoforos, et al.
Publicado: (2022)

The development of a stochastic mathematical model of Alzheimer’s disease to help improve the design of clinical trials of potential treatments
por: Hadjichrysanthou, Christoforos, et al.
Publicado: (2018)

Modelling upper respiratory viral load dynamics of SARS-CoV-2
por: Challenger, Joseph D., et al.
Publicado: (2022)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies
por: Beukenhorst, Anna L., et al.
Publicado: (2023)

Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro
por: Zhang, Leike, et al.
Publicado: (2020)

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis
por: Agyeman, Akosua Adom, et al.
Publicado: (2016)

The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2
por: Ivashchenko, Andrey A., et al.
Publicado: (2022)

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development
por: Cao, Youfang, et al.
Publicado: (2021)

Understanding the within-host dynamics of influenza A virus: from theory to clinical implications
por: Hadjichrysanthou, Christoforos, et al.
Publicado: (2016)

Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections
por: Vegvari, Carolin, et al.
Publicado: (2016)

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
por: Ower, Alison K., et al.
Publicado: (2017)

Within Host Dynamics of SARS-CoV-2 in Humans: Modeling Immune Responses and Antiviral Treatments
por: Ghosh, Indrajit
Publicado: (2021)

The dynamics and efficacy of antiviral RNA silencing: A model study
por: Groenenboom, Marian AC, et al.
Publicado: (2008)

Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape
por: Dang, Shengyuan, et al.
Publicado: (2022)

Mathematical modeling of SARS-CoV-2 viral dynamics and treatment with monoclonal antibodies
por: Kareva, Irina, et al.
Publicado: (2022)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients
por: Romano, Federico, et al.
Publicado: (2021)

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
por: Lowe, David M., et al.
Publicado: (2022)

Applications of the hollow-fibre infection model (HFIM) in viral infection studies
por: Kembou-Ringert, Japhette E, et al.
Publicado: (2022)

Antiviral lectins: Selective inhibitors of viral entry
por: Mitchell, Carter A., et al.
Publicado: (2017)

The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease
por: Hadjichrysanthou, Christoforos, et al.
Publicado: (2020)

The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer’s disease treatment?
por: Evans, Stephanie, et al.
Publicado: (2018)

A hybrid PDE–ABM model for viral dynamics with application to SARS-CoV-2 and influenza
por: Marzban, Sadegh, et al.
Publicado: (2021)

Modeling viral dynamics in SARS-CoV-2 infection based on differential equations and numerical analysis
por: Odaka, Mitsuhiro, et al.
Publicado: (2021)

Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types
por: McCormack, Clare P., et al.
Publicado: (2023)

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
por: Gonçalves, Antonio, et al.
Publicado: (2020)

Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model
por: Jeong, Ju Hwan, et al.
Publicado: (2023)

Distinct viral clades of SARS‐CoV‐2: Implications for modeling of viral spread
por: Brufsky, Adam
Publicado: (2020)

Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2
por: Zhang, Shaojun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44o7fo8ucm9ibf80s93aocsvqo